Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement.
Yan Y, Qu S, Liu J, Li C, Yan X, Xu Z, Qin T, Jia Y, Pan L, Gao Q, Jiao M, Li B, Gale RP, Xiao Z.
Leuk Lymphoma. 2023 Sep;64(9):1605-1610. doi: 10.1080/10428194.2023.2226277. Epub 2023 Jun 24.
Myeloid/lymphoid neoplasm with FGFR1 rearrangement.
Germans SK, Chen M.
Blood. 2021 Sep 9;138(10):912. doi: 10.1182/blood.2021012168.
Myeloid/lymphoid neoplasm associated with eosinophilia and concurrent rearrangement of PDGFRA and FGFR1: A very rare pediatric case.
Wang B, Wang X, Lin J, Zhang Y, Gan W, Li T.
Pediatr Blood Cancer. 2023 Oct;70(10):e30507. doi: 10.1002/pbc.30507. Epub 2023 Jun 19.
Different phenotype relapse of myeloid/lymphoid neoplasms with FGFR1 rearrangement with long remission.
Sugiyama M, Arakawa A, Kogure Y, Shirakawa N, Watanabe M, Ito Y, Tanimura K, Tao K, Nakajima M, Watanabe Y, Miyagi-Maeshima A, Fukuhara S, Kataoka K, Izutsu K, Fukuda T, Ogawa C.
Pediatr Blood Cancer. 2024 Jan;71(1):e30721. doi: 10.1002/pbc.30721. Epub 2023 Oct 13.
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.
Bain BJ.
Haematologica. 2010 May;95(5):696-8. doi: 10.3324/haematol.2009.021675.
Unusual infant eosinophilia: myeloid neoplasm with FGFR1 abnormality.
Li W, Cooley LD.
Blood. 2016 Sep 8;128(10):1440. doi: 10.1182/blood-2016-06-722231.
FGFR1-associated myeloid neoplasm with increased mast cells.
Roth CG, Agha M.
Br J Haematol. 2017 Apr;177(2):172. doi: 10.1111/bjh.14533. Epub 2017 Feb 1.
Histologically heterogeneous pediatric glioneuronal tumor with FGFR1::TACC1 fusion.
Canan F, Daoud EV, Weon JL, Raisanen JM, Burns DK, Hatanpaa KJ, Park JY, Kelley S, Rajaram V.
Clin Neuropathol. 2022 Jul-Aug;41(4):185-189. doi: 10.5414/NP301461.
Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.
Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, Asatiani E, Daver NG.
Ann Oncol. 2018 Aug 1;29(8):1880-1882. doi: 10.1093/annonc/mdy173.
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Freyer CW, Hughes ME, Carulli A, Bagg A, Hexner E.
Expert Rev Anticancer Ther. 2023 Apr;23(4):351-359. doi: 10.1080/14737140.2023.2192930. Epub 2023 Mar 29.
